bioTheranostics discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer. All tests are real time, RT-PCR based assays that are compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and/or surgical samples.
|CancerTYPE ID® is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.|
|Breast Cancer IndexSM predicts the risk of late (post 5 years) recurrence and the likelihood of benefit from extended endocrine therapy.|
|PRÉCIS® Precision Medicine by bioTheranostics includes biomarker profiles for non-small cell lung and colorectal cancer that detect clinically relevant tumor biomarkers.|